PT840603E - Composicao farmaceutica a base de ester etilico de levo-dopa - Google Patents

Composicao farmaceutica a base de ester etilico de levo-dopa

Info

Publication number
PT840603E
PT840603E PT96923037T PT96923037T PT840603E PT 840603 E PT840603 E PT 840603E PT 96923037 T PT96923037 T PT 96923037T PT 96923037 T PT96923037 T PT 96923037T PT 840603 E PT840603 E PT 840603E
Authority
PT
Portugal
Prior art keywords
pharmaceutical composition
ethyl ester
levo
ester based
dopa ethyl
Prior art date
Application number
PT96923037T
Other languages
English (en)
Inventor
Ruth Levy
Sasson Cohen
Yoram Sela
Nava Shterman
Eldad Melamed
Daphne Atlas
Original Assignee
Yissum Res Dev Comp The Hebrew
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Comp The Hebrew, Teva Pharma filed Critical Yissum Res Dev Comp The Hebrew
Publication of PT840603E publication Critical patent/PT840603E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT96923037T 1995-07-21 1996-07-18 Composicao farmaceutica a base de ester etilico de levo-dopa PT840603E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US136895P 1995-07-21 1995-07-21

Publications (1)

Publication Number Publication Date
PT840603E true PT840603E (pt) 2003-01-31

Family

ID=21695690

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96923037T PT840603E (pt) 1995-07-21 1996-07-18 Composicao farmaceutica a base de ester etilico de levo-dopa

Country Status (12)

Country Link
US (1) US5840756A (pt)
EP (1) EP0840603B1 (pt)
JP (1) JPH11509547A (pt)
AT (1) ATE223712T1 (pt)
AU (1) AU6368596A (pt)
CA (1) CA2227208A1 (pt)
DE (1) DE69623634T2 (pt)
DK (1) DK0840603T3 (pt)
ES (1) ES2184881T3 (pt)
IL (1) IL123010A (pt)
PT (1) PT840603E (pt)
WO (1) WO1997003662A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002529407A (ja) * 1998-11-10 2002-09-10 テバ ファーマシューティカル インダストリーズ リミティド L−dopaエチルエステル含有分散性組成物
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
GB0114198D0 (en) * 2001-06-11 2001-08-01 Syngenta Ltd Herbicidal composition
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
US20030135065A1 (en) * 2001-11-13 2003-07-17 Ramy Lidor-Hadas Process for the production of L-DOPA ethyl ester
AU2002340470A1 (en) 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
US20050113452A1 (en) * 2003-10-20 2005-05-26 Moshe Flashner-Barak Composition and dosage form for sustained effect of levodopa
US7342131B2 (en) * 2004-06-04 2008-03-11 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US20080193526A1 (en) * 2005-03-28 2008-08-14 Anders Pettersson Pharmaceutical Compositions Useful in the Treatment of Pain
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
EP1945188A2 (en) * 2005-11-07 2008-07-23 Teva Pharmaceutical Industries Ltd. Levodopa compositions
EP1959948B1 (en) * 2005-12-05 2012-07-18 XenoPort, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
US7829592B2 (en) * 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
TW200843732A (en) * 2006-12-21 2008-11-16 Xenoport Inc Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
AU2008343787B2 (en) 2007-12-28 2014-01-30 Impax Laboratories, Llc Controlled release formulations of levodopa and uses thereof
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
WO2010047775A2 (en) * 2008-10-20 2010-04-29 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
PL3054929T3 (pl) 2013-10-07 2021-05-31 Impax Laboratories, Llc Mukoadhezyjne preparaty lewodopy i / lub estrów lewodopy o kontrolowanym uwalnianiu oraz ich zastosowania
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
KR20230124622A (ko) 2020-12-22 2023-08-25 암닐 파마슈티컬스 엘엘씨 레보도파 투여 요법
WO2025075499A1 (en) 2023-10-02 2025-04-10 Universiteit Van Amsterdam Reducing dopamine feed-back inhibition in dopaminergic cells by tadalafil.
GB2644236A (en) 2024-09-24 2026-03-25 Novumgen Ltd Orodispersible tablet composition containing carbidopa and levodopa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA

Also Published As

Publication number Publication date
DK0840603T3 (da) 2003-01-20
IL123010A (en) 2003-11-23
DE69623634T2 (de) 2003-05-22
WO1997003662A1 (en) 1997-02-06
US5840756A (en) 1998-11-24
ATE223712T1 (de) 2002-09-15
DE69623634D1 (de) 2002-10-17
CA2227208A1 (en) 1997-02-06
ES2184881T3 (es) 2003-04-16
AU6368596A (en) 1997-02-18
IL123010A0 (en) 1998-08-16
EP0840603A1 (en) 1998-05-13
JPH11509547A (ja) 1999-08-24
EP0840603B1 (en) 2002-09-11

Similar Documents

Publication Publication Date Title
ES2184881T3 (es) Composicion farmaceutica de ester etilico de l-dopa.
HUP0003323A2 (hu) Vorikonazolt tartalmazó gyógyászati készítmények
SE9504661D0 (sv) New compounds
RU95108590A (ru) Производные имидазола
ATE306261T1 (de) Antithrombosemittel
ES2178291T3 (es) Uso de acidos 3-benzoil-aceticos, esteres, o amidas para el tratamiento del glaucoma glc1a.
BR9809112A (pt) Novo processo para preparação de uma substância farmacologicamente ativa
NO962841D0 (no) Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler
ATE435648T1 (de) Derivaten von nodulisporen säure
ES2173858T3 (es) Analogos de huperzina a.
UA42819C2 (uk) Ін`єкційний та інфузійний розчин, що містить енрофлокcацин
IT1299583B1 (it) Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
PT975348E (pt) Composicoes de tibolona estabilizadas
PT736029E (pt) Sulfamatos de pseudofructopiranose anticonvulsivos
NO980296L (no) Forbedrede terapeutiske midler
IS1910B (is) Notkun á fankínóni til meðhöndlunar á Alzheimers-sjúkdómi
NO982229D0 (no) Svovelholdige di-tert-butylfenol-forbindelser anvendbare som antiinflammatoriske midler
TR199700963T1 (xx) Kardiyovask�ler hastal�klar�n tedavisi i�in aminotetralin t�revi.
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
TR200002293T2 (tr) Farmasötik bileşimler.
BR9813102A (pt) Derivados de ácido metilenobisfosfÈnico novos
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
ATE206431T1 (de) Antifungal fusacandine
ATE223427T1 (de) Modifizierte kojibioside analoge
FR2732604B1 (fr) Derives et conjugues du mdp presentant une activite stimulatrice de la fonction hematopoietique et compositions les contenant